Tumor antigens recognized by T cells

Boon, Thierry; Coulie, Pierre G.; Eynde, Benoı̂t Van den

doi:10.1016/s0167-5699(97)80020-5

Cited by 475 publications

(321 citation statements)

References 14 publications

Supporting

Mentioning

316

Contrasting

Unclassified

Order By: Relevance

“…21 This is probably due to the fact that many tumorspecific and tumor-associated antigens are weak antigens. 22,23 Therefore we addressed the question of whether Ad/PEI/DNA transduced DC can be exploited to generate antigen-specific MHC class II T cell responses in addition to MHC class I responses. A gene delivery system that achieves both CD4 and CD8 T cell responses simultaneously would be of considerable advantage over the existing DNA transfer systems.…”

Section: Introductionmentioning

confidence: 99%

MHC class II presentation of endogenously expressed antigens by transfected dendritic cells

et al. 2001

View full text Add to dashboard Cite

Dendritic cells (DC) present immunogenic epitopes of antigens in the context of MHC class I and class II molecules in association with costimulatory molecules, and efficiently activate both cytotoxic T cells and T helper cells. Gene modified DC expressing antigen encoding cDNA represent a particularly attractive approach for the immunotherapy of disease. We previously described a gene delivery system for DC based on receptor-mediated endocytosis of ligand/polyethylenimine (PEI) DNA transfer complexes that target cell surface receptors which are abundantly expressed on DC. Employing this gene delivery system, DC were generated that express chicken ovalbumin (OVA) cDNA as a model antigen and introduce antigen into the

show abstract

Section: Introductionmentioning

confidence: 99%

MHC class II presentation of endogenously expressed antigens by transfected dendritic cells

et al. 2001

View full text Add to dashboard Cite

show abstract

“…2,3 In contrast, infections of peripheral solid organs with noncytopathic viruses such as hepatitis B and C virus in humans or lymphocytic choriomeningitis virus ( LCMV ) in mice are largely controlled by activated cytotoxic T lymphocytes (CTLs ), which have the capacity to extravasate and enter the infected peripheral solid tissue; antibodies play virtually no role in this process. 4 Solid tumors, including carcinomas and sarcomas, often express a cell -associated tumor antigen 5,6 and, therefore, resemble viral infections of peripheral tissues in many ways. Similar to protection against noncytopathic viruses, the main effector mechanism of adaptive immunity to control peripheral tumors may be CTL, and antibodies seem to play only a limited role.…”

mentioning

confidence: 99%

Principles of tumor immunosurveillance and implications for immunotherapy

Ochsenbein

2002

Cancer Gene Ther

View full text Add to dashboard Cite

Although antigen loss variants, major histocompatibility ( MHC ) class I down -regulation, or the expression of inhibitory molecules may explain the failure of immunosurveillance against some tumors, this seems not to apply for many other solid peripheral or lymphohematopoietic tumors. Why then is immunosurveillance so ineffective and can it be improved? This review focuses on one important aspect of tumor immunity, namely the relevance of antigen dose and localization. Immune responses in vivo are induced in organized lymphoid tissues, i.e., in lymph nodes and spleen. The antigen dose that reaches secondary lymphoid organs over time is a crucial parameter that drives antiviral and antitumoral immune responses. Tumors use various strategies to prevent efficient presentation of their antigens in lymphoid organs. A major obstacle to the induction of an endogenous tumor -specific cytotoxic T lymphocyte ( CTL ) response is the inefficient presentation of tumor antigen on MHC class I molecules of professional antigenpresenting cells. Peripheral solid tumors that develop outside lymphoid organs are, therefore, often ignored by the immune system. In other situations, tumors -especially of lymphohematopoietic origin -may tolerize specific CTLs. Understanding tumor immunosurveillance is key to the design of efficient antitumor vaccines. Attempts to improve immunity to tumors include vaccination strategies to ( a ) provide the tumor antigen to secondary lymphoid organs using recombinant viruses or dendritic cells as carriers, ( b ) express costimulatory signals on tumor cells, or ( c ) improve the efficiency of cross -priming.

show abstract

“…[17][18][19][20][21][22][23][24] CTL lysis of autologous tumor cells is dependent upon triggering of their T cell receptors (TCR) with a ligand composed of a tumor-associated peptide complexed with an MHC molecule. 25,26 Interferon gamma (IFN␥) has several important immune modulating capacities that might contribute to the optimal development of both types of antitumor response in RCC patients. It can induce expression of MHC class II molecules in epithelial cells that do not constitutively express such molecules.…”

Section: Introductionmentioning

confidence: 99%

Gene transfer of human interferon gamma complementary DNA into a renal cell carcinoma line enhances MHC-restricted cytotoxic T lymphocyte recognition but suppresses non-MHC-restricted effector cell activity

et al. 2000

View full text Add to dashboard Cite

Even though renal cell carcinomas (RCC) are thought to be immunogenic, many tumors express variations in surface molecules and intracellular proteins that hinder induction of optimal antitumor responses. Interferon gamma (IFN␥) stimulation can correct some of these deficiencies. Therefore, we introduced the complementary DNA (cDNA) encoding human IFN␥ into a well-characterized RCC line that has been selected for development of an allogeneic tumor cell vaccine for treatment of patients with metastatic disease. Studies were performed to determine how endogenous IFN␥ expression influences tumor cell immunogenicity. IFN␥ transductants showed minimal increases in surface expression of MHC class I and adhesion molecules but

show abstract

Tumor antigens recognized by T cells

Cited by 475 publications

References 14 publications

MHC class II presentation of endogenously expressed antigens by transfected dendritic cells

MHC class II presentation of endogenously expressed antigens by transfected dendritic cells

Principles of tumor immunosurveillance and implications for immunotherapy

Gene transfer of human interferon gamma complementary DNA into a renal cell carcinoma line enhances MHC-restricted cytotoxic T lymphocyte recognition but suppresses non-MHC-restricted effector cell activity

Contact Info

Product

Resources

About